Sydbank: Expanded ALK approval is good news

It is good news that the FDA has approved ALK's ragweed allergy tablet for use in children – though it won't cause a huge increase in short term sales, says Sydbank senior analyst Søren Løntoft Hansen.
Sydbank/PR | Photo: Sydbank/PR
Sydbank/PR | Photo: Sydbank/PR
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT

From now on, ALK-Abelló will also be able to market its allergy tablet, Ragwitek, as suitable for children aged 5 and above in the US. Although this is of course good news, it isn't something that will generate a lot of sales in the short term, says senior analyst at Sydbank, Søren Løntoft Hansen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading